Adult humans produce more IgA per day than all other antibody isotypes combined 1 . IgA is the predominant antibody isotype in mucosal regions, which represent the primary avenue for invasion by many pathogens. The mucosal immune system is responsible for multiple levels of protection against pathogens: induction of immunity in mucosa-associated lymphoid tissues, prevention of pathogen adherence by secretory IgA-mediated immune exclusion, and systemic immune effector functions through the action of serum antibodies 2 . Two distinct forms of IgA are found in serum: monomeric and dimeric IgA. Monomeric IgA is analogous to IgG and IgE, but has additional carboxy-terminal tailpieces that interact with J-(joining) chain, forming covalent dimeric IgA 3 . Co-expression of IgA and J-chain by B cells in the mucosal lamina propria leads to high local concentrations of dimeric IgA in these regions, whereas serum IgA is predominantly monomeric 1 . Dimeric IgA is specifically bound by pIgR on the basolateral surfaces of the mucosal epithelium, transcytosed through the epithelial layer, and released into mucosal secretions as a covalent complex of dimeric IgA and the cleaved pIgR ectodomain (called bound secretory component, SC) 3 . The complex of dimeric IgA with bound SC is known as secretory IgA (SIgA) and represents a third distinct form of IgA.
IgA-mediated immune effector responses such as phagocytosis, antibody-dependent cell-mediated cytotoxicity, respiratory burst and cytokine release are mediated through FcaRI (CD89), an IgAspecific receptor that is expressed on monocytes, eosinophils, neutrophils and macrophages 4 . Both monomeric and dimeric IgA can bind to FcaRI, and monomeric or dimeric IgA immune complexes can activate phagocytosis and other immune responses through the clustering of FcaRI 5 . SIgA cannot trigger phagocytosis 5, 6 , although it can initiate certain inflammatory responses, such as respiratory burst in polymorphonuclear leukocytes 7 and degranulation of eosinophils 8 , through FcaRI and an integrin co-receptor. Although FcaRI is distantly related to FcgR and Fc1RI proteins, it shares higher sequence similarity with the leukocyte immunoglobulin-like receptors (LIR/LILR/ILTs), killer inhibitory receptors (KIRs) and other members of the leukocyte receptor cluster 9 . Unlike FcgRIII and Fc1RI, which form 1:1 receptor:Fc complexes through interactions with hinge-proximal Fc regions 10, 11 , FcaRI forms a 2:1 complex with an Fca dimer 12 by binding to each C H 2-C H 3 domain interface (called Ca2 and Ca3 in IgA) 13, 14 , reminiscent of the 2:1 complex formed between the neonatal Fc receptor (FcRn) and IgG, in which FcRn binds to the C H 2-C H 3 interface of Fcg 15 . To understand the molecular basis of the FcaRI:IgA interaction, we determined the crystal structures of the FcaRI ectodomain in two crystal forms and a 2:1 FcaRI:Fca complex at resolutions of 3.0, 3.9 and 3.1 Å , respectively (Supplementary Table 1 ).
Structure of FcaRI
The FcaRI ectodomain is composed of two immunoglobulin-like domains oriented at approximately 908 to one another (Fig. 1a) . The domains of FcaRI have a similar folding topology to the domains of LIR-1 (ref. 16 ) and other immunoglobulin superfamily Fc receptors 11, [17] [18] [19] (Fig. 1b; see Supplementary Table 2 for r.m.s. deviations between the domains of FcaRI and other receptors). In both domains 1 and 2 (D1 and D2), the first b-strand is shared between the two b-sheets. D1 includes short C 0 and D strands connecting strands C and E, whereas there is no D strand in D2. There are short stretches of 3 10 helix in both domains, and a polyproline type-II helix in D2 (Fig. 1a) . Ordered carbohydrate is visible at two of the four potential N-linked glycosylation sites in each molecule of free FcaRI in the 3.0 Å structure (N120 and N156 in the first molecule, and N44 and N58 in the second molecule) and at all four sites in the Fca-bound FcaRI structure. The overall domain orientation resembles that seen in the LIR-1 (ref. 16 ; Fig. 1c) 11, [17] [18] [19] , the relative D1-D2 orientation in these receptors is opposite to that observed for FcaRI and LIR-1 (ref. 16 ; Fig. 1c) .
A comparison of three independent structures of free FcaRI (two molecules from the 3.0 Å structure, and one from the 3.9 Å struc-ture) reveals moderate flexibility in the D1-D2 interface; the interdomain angles are 978 and 928 for the two molecules in the 3.0 Å structure, and 888 for the low-resolution model. (Fig. 1d) .
Structure of Fca
The structure of Fca described here is derived from the FcaRI:Fca complex structure, because attempts to crystallize Fca alone were unsuccessful. Fca is a two-fold symmetric dimer of IgA heavy chains, each with two immunoglobulin constant domains, Ca2 and Ca3 (Fig. 2) . The Ca3 domains form an extensive dimer interface that buries a total of 2,061 Å 2 and associate to form similar dimerization contacts to those seen in the analogous Cg3-Cg3 (Fig.  2a) and C14-C14 interactions in Fcg 21 and Fc1 22, 23 , respectively. Apart from minor variations in loop regions, the primary differences between Fca and other Fcs of known structure (Fcg and Fc1) involve the positions of interdomain disulphide bonds and N-linked carbohydrates. Like Fcg, the heavy chains of Fca are covalently coupled through disulphides linking hinge residues (C241 to counterpart C241; not present in our construct) 24, 25 . However, Fca also has unusual disulphides between C299 in the DE loop of each Ca2 domain and C242 at the base of the hinge in the opposite heavy chain (Fig. 2b) . These interdomain disulphide bonds are reminiscent of those observed linking the IgE heavy chains at the base of the C12 domains 22 , although the residues involved are not analogous. Interestingly, Fca C299 is the counterpart of Fcg N297 and Fc1 N394, the residues to which the interdomain N-linked glycans that stabilize the Cg2 or C13 domains are attached. Thus, this substitution in Fca of cysteine for asparagine allows disulphide bond formation and prevents attachment of N-linked glycans between the Ca2 domains, which is a conserved feature of Cg2 domains and the counterpart C13 domains. Instead, Fca contains N-linked carbohydrates attached to N263 on an outer surface of the Ca2 domains (Fig. 2a) . Each N-glycan contacts both the Ca2 and Ca3 domains, burying 465 Å 2 and 457 Å 2 , respectively, unlike the Fcg and Fc1 N-glycans, which contact only the Cg2 (or C13) domains.
Structure of the FcaRI:Fca complex
The FcaRI:Fca complex consists of two FcaRI molecules bound to a single Fca dimer, with one receptor binding at each Ca2-Ca3 interface (Fig. 3a, b) . The FcaRI-binding site on Fca is composed of residues in the AB helix/loop of the Ca2 domain (L256, L257, L258) and several regions of the Ca3 domain: the A strand (E348), the C strand (R382, L384), the CC 0 loop (S387, E389), the F strand (M433, H436), the FG loop (E437, A438, L439, P440, L441) and the G strand (A442, F443, T444, Q445) (Figs 2b and 4a, and Supplementary Table 3 ). These residues are conserved in all human IgA subclasses and allotypes (IgA1, IgA2m(1), IgA2m (2) and IgA2n). Sequence alignment of IgA1 with other antibody isotypes shows that the specificity of FcaRI for IgA appears to arise predominantly from residues in the C strand and CC 0 loop, with contributions from residues in the F strand, FG loop and G strand (Fig. 5) . The site on FcaRI that binds Fca involves residues found in the BC loop (Y35), the D strand (R52, R53, L54, K55), the DE loop (F56, W57, carbohydrate linked to N58), and the FG loop (R82, G84, H85) of D1 (Figs 1b and 4a, and Supplementary Table 3) . A similar region of LIR-1 has been mapped as the binding site for UL18, a viral major histocompatibility complex (MHC) class I homologue 16 . The FcaRI:Fca interface is composed of a central hydrophobic core (FcaRI residues Y35, L54, F56, G84, H85 and the aliphatic portion of K55 packing against Fca residues L257, L258, M433, L441, A442, F443 and the aliphatic portion of the R382 side chain) flanked by charged residues (FcaRI R52, R53, K55 and R82, and Fca R382, E389 and E437) (Fig. 4b) , burying a total of 1,656 Å 2 . Several potential intermolecular hydrogen bonds are found at the periphery of the site, but no salt bridges are observed, consistent with binding studies showing that ,10% of the free energy of binding is contributed by electrostatic interactions 12 . The N-glycan attached to FcaRI N58 forms two potential hydrogen bonds and a van der Waals contact with Fca (Fig. 4a) . Although the observed N-glycans on Fca approach within 8 Å of FcaRI, they do not directly contact the receptor.
The interaction surface identified by the FcaRI:Fca structure can be used to interpret mutagenesis studies 13, 14, [26] [27] [28] (Fig. 4c) . Substitution of FcaRI Y35, R82 or Y81 to alanine, or H85 to arginine resulted in 100-fold loss of affinity or ablation of binding 27, 28 . Y35 is located at the centre of the hydrophobic patch in the binding site and forms a potential hydrogen bond to the carbonyl oxygen of Fca L257. R82 forms a hydrogen bond with the carbonyl oxygen of Fca L256. Y81 is located in the hydrophobic core of FcaRI D1 and is likely to be essential for proper folding of the domain. H85 interacts with the Fca FG loop. Mutations of FcaRI R52, I83 or G84 to alanine resulted in 8-to 19-fold losses of affinity 28 . R52 forms two potential hydrogen bonds with the carbonyl oxygen of L258, G84 contacts the FG loop, and I83 appears to stabilize the conformation of the FcaRI FG-binding loop, although it does not contact Fca. Mutation of Fca residues in the AB helix/loop (L257R or L258R), the FG loop (P440A, L441R, A442R, L441M/A442N) or the G strand (F443R) resulted in ablation of binding in rosetting assays 13, 14 ; these residues are all involved in the observed FcaRI:Fca interface, and all but one contribute to the hydrophobic core of the binding site.
The FcaRI:Fca structure reveals other residues in the binding site that had not been identified previously, including FcaRI residues in the D strand (L54, K55, F56, W57) and N58-linked sugar, and Fca residues in the Ca2 AB helix/loop (L256), the Ca3 A (E348), C (R382, L384), F (M433, H436) and G (Q445) strands, and the CC 0 (S387, E389) and FG loops (E437, A438, L439). In particular, FcaRI residues L54, K55 and F56 seem to be important for binding, as each makes three to five contacts with Fca and contributes 16%, 9% or 10%, respectively, of the buried surface area in the interface (Supplementary Table 3 ).
Conformational changes on complex formation
Several conformational changes occur within FcaRI D1 on binding Fca. Superposition of D1 in the free and bound receptors shows that the FcaRI D strand and the DE and FG loops adopt different conformations (Fig. 1d, e) . The D strand in free FcaRI shifts from the front b-sheet (strands ABED) to the back b-sheet (strands A 0 GFCC 0 ) on binding Fca, forming instead a C 0 strand in the complex. The main secondary structural elements of FcaRI that participate in binding to Fca (the D/C 0 strand and the DE/C 0 E and FG loops) show inherent flexibility in free FcaRI, and they adopt new conformations on binding (Fig. 1d) . A comparison of the structure of Fc1RI in several crystal forms showed similar structural variability in the analogous regions of D2 (ref. 29) . No significant change in the angle between FcaRI domains occurs on binding to Fca; the D1-D2 angle when bound to Fca (968) is nearly identical to that observed for one molecule of free FcaRI (978) and similar to the other two molecules of free FcaRI (888, 928).
Free Fcg 24 and Fc1 22, 23 show significant conformational changes on binding to FcgRIII 11 or Fc1RI 10 , respectively. These conformational changes induce asymmetry in the Fc molecules when the FcR binds. By contrast, the Fca dimer in the FcaRI:Fca structure is two-fold symmetric. Since the structure of free Fca is not known, it is not clear whether any conformational changes occur when FcaRI binds. However, the disulphide bonds at the top of the Ca2 domains and the large interface between the Ca3 domains burying a total of 2,061 Å 2 would be expected to constrain the conformational freedom of Fca.
Comparison to other FcR:Fc interactions
The Ca2-Ca3 interface of Fca where FcaRI binds is analogous to the Cg2-Cg3 interface on Fcg that serves as the binding site for a number of structurally distinct proteins, including FcRn 15 ( Fig. 3c) 33 . The binding of these proteins to Fcg involves residues in the AB loop of the Cg2 domain and the G strand of the Cg3 domain that create a hydrophobic and highly accessible surface 33 . Although the FcaRI-binding site on Fca also incorporates these regions, none of the residues is conserved exactly between FcaRI:Fca and the other complexes. However, the Fca and Fcg binding surfaces share the common property of being primarily hydrophobic with outlying charged residues.
FcaRI is structurally similar to FcgRIII and Fc1RI, yet the FcaRI:Fca binding interaction is completely different from the FcgRIII:Fcg and Fc1RI:Fc1 complexes, in which a single Fc receptor binds across both Cg2 (or C13) domains in a region adjacent to the Fcg hinge or the Fc1 C12 domains 10, 11 (Fig. 3d, e) . Furthermore, Fca is bound to FcaRI in an 'upright' orientation with its C termini presumably near the membrane, whereas both Fcg and Fc1 are bound by their receptors in the opposite orientation 10, 11 (Fig. 3) . The 'upside-down' orientation of receptor-bound IgG and IgE antibodies probably does not cause steric hindrance between the Fabs and the cell surface, because the hinge region of IgG antibodies is highly flexible 34 , and the Fc region of IgE has a sharp bend between the C12 and C13-C14 domains 22 . By contrast, IgA1 has a heavily O-glycosylated hinge region, which probably adopts a rigid conformation 35 . Thus, the IgA1 hinge is unlikely to be flexible enough to allow binding in the mode observed in the FcgRIII:Fcg and Fc1RI:Fc1 complexes. It is potentially relevant that IgA2 has a 13-residue deletion in the hinge region, eliminating the O-glycosylated region 1 ; binding of FcaRI to the Ca2-Ca3 junction therefore allows identical interactions with both subclasses of IgA, which would be unlikely if FcaRI bound IgA in a hinge-proximal region.
Implications for signalling through FcaRI
Both monomeric and dimeric forms of serum IgA are able to bind and initiate immune effector functions through FcaRI 5 . The primary function of SIgA seems to be immune exclusion, an FcaRI-independent process in which SIgA binds to pathogens and sterically prevents their adherence to the mucosal epithelia 1,2 . SIgA is unable to trigger phagocytosis 5, 6 , although it can initiate respiratory burst in polymorphonuclear leukocytes 7 , and degranulation of basophils and eosinophils 8, 36 . Binding of polymorphonuclear leukocytes to immobilized SIgA 7 and degranulation of eosinophils 8 both show an absolute requirement for the integrin co-receptor Mac-1 (or its b-subunit, CD18), suggesting that SIgA is unable to bind or activate FcaRI alone without the integrin coreceptor. The inability of SIgA to bind or activate FcaRI can be explained based on the structural information presented here. Bound SC in SIgA interacts with IgA residues in the DE and FG loops 37, 38 and forms a disulphide bond with C311 of IgA 3 . As described above, the FG loop comprises a major part of the FcaRI-binding site on Fca (contributing 23% of the total binding surface; Supplementary Table 3) , and C311 is located only 10 Å away; therefore, bound SC occludes some or all of the FcaRIbinding site(s) in SIgA, apparently preventing binding and activation of FcaRI in the absence of the Mac-1 co-receptor.
FcaRI binds IgA with a 2:1 stoichiometry, as shown here by the co-crystal structure and by independent techniques in solution 12 . The 2:1 stoichiometry raises an interesting question: if IgA alone (in the absence of antigen) is able to dimerize FcaRI, what prevents constitutive activation of FcaRI by free IgA? There are several potential explanations. First, the C termini of the two FcaRI molecules in the FcaRI:Fca complex are separated by 124 Å , which may be too far apart to register as a receptor dimerization event triggering downstream signalling. Second, the concentration of IgA in serum is typically 20 mM, which is 50-to 100-fold above the K d for the FcaRI:IgA binding interaction 12 . Under such conditions, 1:1 complexes of FcaRI with free IgA would dominate. Due to the moderately fast on-and off-rates of the FcaRI:IgA binding reaction (2 £ 10 5 (M s) 21 and 0.04 s 21 , respectively) 12 , rapid sampling of free IgA would occur. By contrast, the multivalent nature of interactions between FcaRI and an IgA-immune complex would lead to a very slow off-rate, allowing stable binding and phagocytosis of an IgA-bound antigen even in the presence of high free IgA concentrations in serum. Finally, the cytoplasmic domain of FcaRI interacts with the cytoskeleton, and this interaction can be modulated by addition of cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) 39 . GM-CSF stimulates a rapid increase in phagocytosis and affinity of FcaRI for IgA 40 , indicating that cytokine priming may initiate a change in local FcaRI surface density and, therefore, avidity for IgA. These findings suggest that the tethering of FcaRI to the cytoskeleton could spatially restrict FcaRI, preventing clustering until priming of the immune cell with an activating cytokine occurs 12 . A
Methods Crystallization and data collection
The ectodomain of FcaRI and the Fc fragment of IgA1 were expressed and purified as described 12 . Crystals of FcaRI were grown in hanging drops containing 20% PEG-8000 and 0.1 M MES, pH 6.0 (FcaRI crystal form I; space group I4 1 , two molecules in the asymmetric unit) or 20% PEG-8000 and 0.1 M sodium phosphate, pH 6.0 (FcaRI crystal form II; space group I2 1 2 1 2 1 , two molecules per asymmetric unit). Crystals of the FcaRI:Fca complex were grown from 2:1 molar ratio mixtures of FcaRI and Fca in 1.7-1.85 M magnesium sulphate heptahydrate and 0.1 M MES, pH 6.5-6.7, in space group P3 with one 2:1 FcaRI:Fca complex per asymmetric unit. Data processing and scaling was carried out using the HKL package 41 (Supplementary Table 1 ). Although the complex dataset was only 72% complete in the highest-resolution shell (3.2-3.1 Å ), the data were 90% and 99% complete in the next-highest-resolution shells (3.3-3.2 Å and 3.5-3.3 Å , respectively).
Structure determination and refinement
Phases for crystal form I of FcaRI were determined by a combination of multiwavelength anomalous diffraction (MAD) and multiple isomorphous replacement with anomalous scattering (MIRAS) using trimethyl lead acetate and uranyl acetate derivatives. Five lead positions were determined by the program SOLVE 42 using all three wavelengths in the MAD data set. Five uranium positions were then determined by anomalous difference Fourier analysis. MIRAS phases were calculated using SHARP 43 , giving an overall figure of merit of 0.24 from 25-3 Å . Solvent flipping with SOLOMON 44 gave a readily interpretable map containing essentially the entire first FcaRI molecule and most of the second FcaRI molecule. Refinement was carried out using all reflections with F . 0 (no sigma cuts were applied) using cycles of torsional, positional and grouped B-refinement with a bulk solvent correction in CNS 45 with the maximum likelihood Hendrickson-Lattman (MLHL) target using MIRAS phases without solvent flipping. The refinement initially used noncrystallographic symmetry (NCS) constraints; later stages incorporated NCS restraints (300 kcal mol The structure of crystal form II of FcaRI was determined by molecular replacement using AMoRe 46 with coordinates from the form I structure; the molecular replacement search and subsequent rigid-body refinement gave significantly higher correlation coefficients and lower R-values in I2 1 2 1 2 1 than in I222. Both molecules in crystal form II were subjected to rigid-body refinement followed by a single round of torsional refinement with a bulk solvent correction and NCS constraints (R cryst ¼ 35.2%, R free ¼ 39.0%). The starting model had B-factors arbitrarily fixed at 40 Å 2 ; other than the bulk solvent correction, no B-factor refinement was carried out. The resulting model was not refined further owing to the limited resolution of the data.
The FcaRI:Fca complex was solved by molecular replacement using AMoRe 46 . A polyalanine version of Fcg (1DN2.pdb 33 ) and the refined structure of FcaRI (crystal form I) were used as search models, yielding a clear solution in space group P3. The model for a half-complex (one Fca heavy chain and one FcaRI molecule) was subjected to rigid-body refinement followed by torsional, positional and grouped B-factor refinement using all reflections with F . 0. We incorporated a bulk solvent correction and used NCS constraints initially and NCS restraints (300 or 200 kcal mol 21 Å 2 ) in later rounds, yielding a final model (R cryst ¼ 25.1%, R free ¼ 28.4%) that includes residues 242-450 of each Fca heavy chain; residues 6-195 of FcaRI; 20 N-acetyl glucosamine, 20 mannose, two fucose and two sialic acid residues. The overall B-factors by domain for all protein atoms in the half-complex (and the NCS-related half-complex) are: Fca Ca2, 88. ). For analyses of interdomain angles, contacts and buried surface areas, FcaRI D1 was defined as residues 6-100 and D2 was defined as residues 101-198; Fca Ca2 was defined as residues 242-342 and Ca3 was defined as residues 343-450. Interdomain contact residues were defined as residues within 4 Å of another domain and identified using CNS 45 . Potential hydrogen bonds were identified according to established criteria 47 , using the program HBPLUS 47 . Buried surface areas were calculated using AREA from the CCP4 program suite 44 with a 1.4 Å probe. Angles between domains were calculated using DOM_ANGLE 48 , which determines the angle between the long axes of adjacent domains that are approximated by ellipsoids calculated from the coordinates. Figures were generated using Molscript 49 and Raster3D
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. Figure 5 Alignment of antibody Fc sequences. Residues that make up the FcaRI-binding site in IgA1, or exact matches in other isotypes, are in red. Closely matched residues (that is, conserved hydrophobicity or charge) are in yellow. Similar residues (that is, E ! Q substitution) are in blue. The secondary structure of Fca is illustrated above the sequences. Carets (^) and asterisks (*) denote residues that contribute 0-4% or 5-12%, respectively, of the binding surface.
